Soetkin Vlassak
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States.
Journal: Clinical lung cancer
Published: January 07, 2026
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.
Journal: Clinical lung cancer
Published: October 28, 2024
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion.
Journal: The oncologist
Published: December 19, 2023
Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC.
Journal: Clinical colorectal cancer
Published: December 18, 2023
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.
Journal: Future oncology (London, England)
Published: March 31, 2023
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Journal: Clinical journal of oncology nursing
Published: September 15, 2022
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Journal: Clinical lung cancer
Published: November 19, 2021
Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Journal: Cancer medicine
Published: March 05, 2019
Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 12, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 17, 2018
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 24, 2018
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).
Journal: British journal of cancer
Published: April 09, 2014
Last Updated: 09/26/2026